Two Labs, an industry-leading pharma and life science services company, announced at Asembia’s 2018 Specialty Pharmacy Summit that Anita Dopkosky, a pharmaceutical industry executive, has joined the Commercialization team as Vice President of Specialty Pharmacy.
Dopkosky will be responsible for helping pharma and biotech manufacturers develop efficient, cost-effective distribution models to serve patients, caregivers and prescribing physicians. In addition, she will work with trading partners to identify areas of collaboration within the specialty pharmacy and distribution space, supporting the company’s broader purpose in helping patients get access to life-altering drugs and services.
“There is no one-size-fits-all distribution model – and Anita believes it’s essential to fully understand the patient’s journey and the unique attributes of the product,” said Will Pih, PharmD, Principal and EVP of Specialty Commercialization at Two Labs. “We are overjoyed to welcome Anita to the Two Labs team. Our culture is centered around the drive to support patients, and I am confident that her experience, leadership and commitment to our core values will position her as a great asset for our clients.”
Before joining Two Labs, Dopkosky served as an organizational leader for specialty pharmacy business development and implementation at Walgreens Boots Alliance – where she helped secure access for biopharma’s limited distribution products that required strategic and tailored high-touch services. Prior to Walgreens, Dopkosky held ascending and complementary positions at McKesson and Thermo Fisher Scientific.
Dopkosky is just one of six new hires in the past 18 months, which speaks to the ongoing, significant growth of the Two Labs Specialty team.
“Two Labs demonstrates a strong commitment to innovation, collaboration and quality client service, and I am excited about the opportunity to work with the company and its broad array of existing service lines,” said Dopkosky. “Two Labs has raised the bar when it comes to customizing their commercialization platform, and I look forward to bringing added value to the table.”